Cargando…
Impacts of Diabetes and an SGLT2 Inhibitor on the Glomerular Number and Volume in db/db Mice, as Estimated by Synchrotron Radiation Micro-CT at SPring-8
BACKGROUND: Recent large-scale clinical studies demonstrate that sodium-glucose cotransporter 2 (SGLT2) inhibitors protect the diabetic kidney. However, clinical and animal studies have not shown the changes of the total glomeruli in the whole kidney treated with SGLT2 inhibitors. METHODS: We perfor...
Autores principales: | Takiyama, Yumi, Sera, Toshihiro, Nakamura, Masanori, Ishizeki, Kanaki, Saijo, Yasuaki, Yanagimachi, Tsuyoshi, Maeda, Manami, Bessho, Ryoichi, Takiyama, Takao, Kitsunai, Hiroya, Sakagami, Hidemitsu, Fujishiro, Daisuke, Fujita, Yukihiro, Makino, Yuichi, Abiko, Atsuko, Hoshino, Masato, Uesugi, Kentaro, Yagi, Naoto, Ota, Tsuguhito, Haneda, Masakazu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197731/ https://www.ncbi.nlm.nih.gov/pubmed/30322799 http://dx.doi.org/10.1016/j.ebiom.2018.09.048 |
Ejemplares similares
-
Hypoxia-inducible factor-1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy
por: Bessho, Ryoichi, et al.
Publicado: (2019) -
High glucose induces platelet‐derived growth factor‐C via carbohydrate response element‐binding protein in glomerular mesangial cells
por: Kitsunai, Hiroya, et al.
Publicado: (2016) -
Increment of plasma glucose by exogenous glucagon is associated with present and future renal function in type 2 diabetes:a retrospective study from glucagon stimulation test
por: Takeda, Yasutaka, et al.
Publicado: (2019) -
Dipeptidyl peptidase-4 inhibitor treatment induces a greater increase in plasma levels of bioactive GIP than GLP-1 in non-diabetic subjects
por: Yanagimachi, Tsuyoshi, et al.
Publicado: (2016) -
A case of insulinoma diagnosed postpartum with hypoglycemic symptoms that were masked during pregnancy
por: Abe, Tomoe, et al.
Publicado: (2021)